洪橋集團(08137.HK)年度純利11.57億港元 同比增長178%
格隆匯3月24日丨洪橋集團(08137.HK)發佈公吿,截至2020年12月31日止年度,公司收益2.97億港元,同比減少13%;公司擁有人應占溢利11.57億港元,同比增長178%;每股盈利11.88港仙。
溢利大幅增加主要歸因於(1)勘探及評估資產大幅撥回減值,原因是與Sul Americanade MetaisS.A.項目有關的勘探及評估資產可收回金額增加;(2)物業、廠房及設備減值虧損減少及(3)該年度的毛利增加。溢利增加部分被與浙江鋰離子電池項目有關的存貨減值虧損、視作出售一間附屬公司的虧損、按公平值計入損益的金融資產的虧損增加及該年度應占聯營公司虧損增加所抵銷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.